Cellosaurus logo
expasy logo

Cellosaurus 8305C (CVCL_1053)

[Text version]
Cell line name 8305C
Synonyms 8305c; 8305-C; 8305C_1
Accession CVCL_1053
Resource Identification Initiative To cite this cell line use: 8305C (RRID:CVCL_1053)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: TCGA-110-CL cell line panel.
Population: Japanese.
Doubling time: 43 hours (PubMed=21566963); ~54 hours (DSMZ=ACC-133); ~50 hours (Note=Lot 07252003) (JCRB=JCRB0824).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Derived from site: In situ; Thyroid gland; UBERON=UBERON_0002046.
Sequence variations
  • Mutation; HGNC; HGNC:795; ATM; Simple; p.Gln2800Ter (c.8398C>T); ClinVar=VCV001171818; Zygosity=Heterozygous (PubMed=30737244; Cosmic-CLP=906795; DepMap=ACH-001306).
  • Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23833040; PubMed=30737244; Cosmic-CLP=906795; DepMap=ACH-001306).
  • Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Phe90Leufs*14 (c.270delT); Zygosity=Heterozygous (PubMed=30737244).
  • Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244; PubMed=31068700).
  • Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Homozygous (PubMed=14522906; PubMed=21566963; PubMed=30737244; Cosmic-CLP=906795; DepMap=ACH-001306).
HLA typing Source: PubMed=26589293
Class I
HLA-AA*11:01,11:01
HLA-BB*15:01,54:01
HLA-CC*01:02,04:01
Class II
HLA-DQDQB1*04:02,04:02
HLA-DRDRB1*11:14,11:14
Genome ancestry Source: PubMed=30894373

Origin% genome
African0
Native American1.04
East Asian, North74.78
East Asian, South24.09
South Asian0
European, North0
European, South0.09
Disease Thyroid gland anaplastic carcinoma (NCIt: C3878)
Anaplastic thyroid carcinoma (ORDO: Orphanet_142)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Female
Age at sampling 67Y
Category Cancer cell line
STR profile Source(s): Cosmic-CLP=906795; DSMZ=ACC-133; ECACC=94090183; JCRB=JCRB0824; PubMed=25877200; PubMed=30737244; RCB=RCB1909; TKG=TKG 0446

Markers:
AmelogeninX
CSF1PO9,12
D2S133817,25
D3S135815
D5S81810,13
D7S8208 (DSMZ=ACC-133)
8,10 (Cosmic-CLP=906795; ECACC=94090183; JCRB=JCRB0824; PubMed=25877200; PubMed=30737244; RCB=RCB1909; TKG=TKG 0446)
D8S117911,14
D13S3179
D16S53910,11
D18S5113,24
D19S43314
D21S1130,32.2
FGA21,22
Penta D10
Penta E15,17
TH016,7
TPOX8
vWA14,16

Run an STR similarity search on this cell line
Publications

PubMed=21566963; DOI=10.3892/ijo.4.3.583
Ito T., Seyama T., Hayashi Y., Hayashi T., Dohi K., Mizuno T., Iwamoto K.S., Tsuyama N., Nakamura N., Akiyama M.
Establishment of 2 human thyroid-carcinoma cell-lines (8305C, 8505C) bearing p53 gene-mutations.
Int. J. Oncol. 4:583-586(1994)

PubMed=9177455; DOI=10.1016/S0304-3835(97)04742-3
Satake S., Sugawara I., Watanabe M., Takami H.
Lack of a point mutation of human DNA topoisomerase II in multidrug-resistant anaplastic thyroid carcinoma cell lines.
Cancer Lett. 116:33-39(1997)

PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D
Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Screening the p53 status of human cell lines using a yeast functional assay.
Mol. Carcinog. 19:243-253(1997)

PubMed=14522906
Frasca F., Vella V., Aloisi A., Mandarino A., Mazzon E., Vigneri R., Vigneri P.
p73 tumor-suppressor activity is impaired in human thyroid cancer.
Cancer Res. 63:5829-5837(2003)

PubMed=15613457; DOI=10.1677/erc.1.00818
Onda M., Emi M., Yoshida A., Miyamoto S., Akaishi J., Asaka S.-i., Mizutani K., Shimizu K., Nagahama M., Ito K., Tanaka T., Tsunoda T.
Comprehensive gene expression profiling of anaplastic thyroid cancers with cDNA microarray of 25 344 genes.
Endocr. Relat. Cancer 11:843-854(2004)

PubMed=16924234; DOI=10.1038/sj.onc.1209899
Yu W., Imoto I., Inoue J., Onda M., Emi M., Inazawa J.
A novel amplification target, DUSP26, promotes anaplastic thyroid cancer cell growth by inhibiting p38 MAPK activity.
Oncogene 26:1178-1187(2007)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113
Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23833040; DOI=10.1210/jc.2013-2383; PMCID=PMC3763971
Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M., Ibrahimpasic T., Ghossein R.A., Fagin J.A.
Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953; PMCID=PMC6522280
Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C., Copland J.A. 3rd, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N., Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R., Fagin J.A., Schweppe R.E.
Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies.
Clin. Cancer Res. 25:3141-3151(2019)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31395879; DOI=10.1038/s41467-019-11415-2; PMCID=PMC6687785
Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M., van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.
Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.
Nat. Commun. 10:3574.1-3574.11(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023; PMCID=PMC7339254
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. 3rd, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers) CLS; 305101
DSMZ; ACC-133
ECACC; 94090183
ICLC; HTL96026
JCRB; JCRB0824
NCBI_Iran; C597
RCB; RCB1909
TKG; TKG 0446
Cell line databases/resources CLO; CLO_0001510
CLO; CLO_0050949
CLDB; cl132
CLDB; cl133
cancercelllines; CVCL_1053
CCRID; 3101HUMSCSP540
Cell_Model_Passport; SIDM00997
CGH-DB; 53-1
Cosmic-CLP; 906795
DepMap; ACH-001306
DSMZCellDive; ACC-133
LINCS_LDP; LCL-1685
Anatomy/cell type resources BTO; BTO_0000919
Biological sample resources BioSample; SAMN01821670
BioSample; SAMN03470959
BioSample; SAMN03473414
BioSample; SAMN10988447
CRISP screens repositories BioGRID_ORCS_Cell_line; 318
Chemistry resources ChEMBL-Cells; CHEMBL3308706
ChEMBL-Targets; CHEMBL1075386
GDSC; 906795
PharmacoDB; 8305C_30_2019
PubChem_Cell_line; CVCL_1053
Encyclopedic resources Wikidata; Q54605326
Experimental variables resources EFO; EFO_0022717
Gene expression databases ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM886846
GEO; GSM887910
GEO; GSM1669573
Polymorphism and mutation databases Cosmic; 906795
Cosmic; 922364
Cosmic; 2009523
Cosmic; 2054104
Cosmic; 2613247
Cosmic; 2786687
IARC_TP53; 21156
LiGeA; CCLE_684
Progenetix; CVCL_1053
Proteomic databases PRIDE; PXD030304
Sequence databases EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update19-Dec-2024
Version number45